Carter Ledyard client, PainReform Ltd., a clinical stage Israeli biotechnology company focused on the reformulation of established therapeutics, was advised by Carter Ledyard’s Steven J. Glusband and Guy Ben-Ami, together with Israeli firm Doron Tikotzky Kantor Gutman & Amit Gross, in its $20,000,000 initial public offering on September 1, 2020. PainReform’s proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
